Top researchers are discussing notable developments in neuroscience, including research in many neuromuscular diseases, at the annual American Academy of Neurology meeting April 21-28
Top scientists and clinicians from around the world are discussing the latest research in neuroscience, and the care of individuals with nerve and muscle diseases, at the 2012 annual meeting of the American Academy of Neurology in New Orleans, April 21-28.
The pace of research can seem unreasonably slow; here are a few reasons why
John Porter from the National Institutes of Health likes to start talks by noting, “It’s a great time to be a mouse with a neuromuscular disease.” Exciting research results are regularly reported, where a treatment appears to cure one neuromuscular disease or another in a mouse — yet there are few treatments available today for people with any of these diseases, and only a few treatments in human...
The biggest problem at an ER may not be the one you go in with, but the one you encounter there
When a medical emergency strikes — and the patient is a person with a neuromuscular disease — it’s not just getting to the emergency room quickly that’s critical. It’s also critical to ensure the ER staff understands the patient’s special needs caused by muscle disease.
Scientists know more about familial ALS (FALS) than sporadic ALS; FALS research may have application for both forms of the disease, however.
The state of research in the familial (inherited) form of ALS was the focus of a special one-hour Webinar presented by the ALS Therapy Development Institute (ALS TDI) on March 25, with reports by CEO & Chief Scientific Officer Steve Perrin.
After a two-year review, the FDA approves reopening a clinical trial of the experimental compound arimoclomol.
A clinical trial of an experimental drug for ALS -- halted almost two years ago due to safety concerns –- has been given the green light to continue with a revised protocol, says CytRx Corp. of Los Angeles, the drug’s manufacturer.
The U.S. Food and Drug Administration placed a hold on the phase 2b trial of arimoclomol in January 2008, saying it wanted to see more toxicity data from previously...
A new type of ALS research mouse, with a mutation in the TDP43 gene, has been developed
Mice carrying a mutation in the gene for the TDP43 protein that's known to cause amyotrophic lateral sclerosis (ALS) in humans have been developed by MDA-supported scientists at Washington University School of Medicine in St. Louis. The mice may provide an important new research tool in this deadly disease.
Eliminating a protein enhanced cellular cleanup, saved nerve cells and prolonged survival in female ALS mice
New research supports strategies that augment a natural process in the nervous system called autophagy – a cellular cleanup and garbage-disposal system — as a possible therapeutic avenue in amyotrophic lateral sclerosis (ALS).
Autophagy (literally "self-eating") is activated when large amounts of debris and abnormal cellular components require destruction.